TD Cowen lowered the firm’s price target on Avita Medical (RCEL) to $12.50 from $15 and keeps a Buy rating on the shares. Avita reiterated its 2025 guidance despite reporting Q1 sales shy of Street expectations, notes the analyst, who contends that the next few quarters will be “a critical period” for key new growth drivers to gain traction.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCEL:
- AVITA Medical Reports Strong Q1 2025 Growth
- Avita Medical: Strong Growth Potential and Strategic Product Launches Justify Buy Rating
- Avita Medical reports Q1 EPS (53c), consensus (51c)
- RCEL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Avita Medical announces U.S. commercial launch of Cohealyx